Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors

Ann Intern Med. 2006 Nov 7;145(9):660-4. doi: 10.7326/0003-4819-145-9-200611070-00008.

Abstract

Background: Sunitinib malate is an oral tyrosine kinase inhibitor recently approved for the treatment of gastrointestinal stromal tumors and renal cell carcinoma. Because the ret proto-oncogene is also inhibited by this agent, clinical evaluation of thyroid function was performed.

Objective: To describe the prevalence and clinical presentation of thyroid dysfunction related to sunitinib therapy.

Design: Prospective, observational cohort study.

Setting: Tertiary care hospital.

Patients: 42 patients treated for a median of 37 weeks (range, 10 to 167 weeks).

Measurements: Following analysis of serial thyroid-stimulating hormone (TSH) measurements collected prospectively during a clinical trial of sunitinib, the authors determined the proportion of patients with thyroid dysfunction.

Results: Abnormal serum TSH concentrations were documented in 26 of 42 patients (62%): 15 (36%) developed persistent, primary hypothyroidism; 4 (10%) developed isolated TSH suppression; and 7 (17%) experienced transient, mild TSH elevations. The risk for hypothyroidism increased with the duration of sunitinib therapy. Six of 15 (40%) hypothyroid patients had suppressed TSH concentrations before developing hypothyroidism, suggesting thyroiditis. Two hypothyroid patients evaluated with thyroid ultrasonography had no visualized thyroid tissue despite normal baseline thyroid function.

Limitations: The exploratory nature of this study precluded more frequent biochemical and sonographic analysis that may better define the mechanism of sunitinib-associated thyroid dysfunction.

Conclusion: Hypothyroidism is a frequent complication of sunitinib therapy. Regular surveillance of thyroid function is warranted in patients receiving the drug. Although the mechanism by which this complication occurs is unknown, the observations of preceding TSH suppression and subsequent absence of visualized thyroid tissue in some patients suggest that sunitinib may induce a destructive thyroiditis through follicular cell apoptosis. This provides a rationale for further investigation of sunitinib treatment in patients with advanced thyroid cancer.

Publication types

  • Case Reports
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Drug Administration Schedule
  • Female
  • Gastrointestinal Stromal Tumors / blood
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Humans
  • Hypothyroidism / chemically induced*
  • Indoles / administration & dosage
  • Indoles / adverse effects*
  • Prospective Studies
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrroles / administration & dosage
  • Pyrroles / adverse effects*
  • Sunitinib
  • Thyroiditis / chemically induced
  • Thyrotropin / blood

Substances

  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Thyrotropin
  • Protein-Tyrosine Kinases
  • Sunitinib